FDA Accepts NDA For Once-Daily Fixed Dose Combination Of Onglyza And Extended Release Metformin

Wed, 03/17/2010 - 5:40am

Bristol-Myers Squibb Company and AstraZeneca today announced that the FDA has accepted for review a New Drug Application (NDA) for an investigational fixed dose combination of ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 (DPP4) inhibitor, and metformin HCl extended-release tablets as a once-daily treatment for type 2 diabetes mellitus in adults. Bristol-Myers Squibb and AstraZeneca submitted the NDA with the U.S. FDA for saxagliptin/metformin HCl extended-release tablets on December 29, 2009.

The NDA is based on bioequivalence data and data from the ONGLYZA phase 3 clinical trial program which included studies for the co-administration of ONGLYZA and immediate release metformin, as an adjunct to diet and exercise, in adult patients with type 2 diabetes inadequately controlled on metformin alone and in treatment-naïve adult patients.



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.